Skip to main content
. 2020 Apr 9;5(7):e133757. doi: 10.1172/jci.insight.133757

Figure 4. HER2-affinity affects the killing activity of anti-HER2/CD3.

Figure 4

(A) SKBR3 cells were treated with HER2 affinity variants of anti-HER2/CD3 TDB. (B) CHO cells were transfected to express cyno-HER2 and treated with HER2–TDB 1 (red) or HER2–TDB 3 (blue). Viability was measured using Cell Titer Glo. Data presented as mean ± SD (n = 3).